Eli Lilly and Company announced initiation of a novel Phase III clinical trial on 3 August for LY-CoV555, the antibody it is developing with AbCellera Biologics Inc. for the potential prevention of COVID-19. The company is deploying specially outfitted recreational vehicles (RVs) to enroll up to 2,400 US nursing home residents and employees at facilities where a patient has been infected.
The BLAZE-2 study will assess whether a single dose of LY-CoV555 can prevent infection with the SARS-CoV-2 virus through four...






